

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司**

**AIDIGONG MATERNAL & CHILD HEALTH LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 286)**

## **INSIDE INFORMATION AND CONTINUED SUSPENSION OF TRADING**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

### **ARBITRATION INITIATED IN THE NAME OF SHENZHEN AIDIGONG**

References are made to the announcements of the Company dated 17 January 2025, 5 March 2025, 13 March 2025 and 18 March 2025 (the “**Announcements**”) in relation to, among others, (i) Ms. Zhu Yufei’s disagreement with Guangdong Wanjia regarding the exercise of shareholders rights in Shenzhen Aidigong; and (ii) Ms. Zhu Yufei’s refusal to return the registered company chop and other relevant company assets of Shenzhen Aidigong to the Group, despite that the shareholders of Shenzhen Aidigong have unanimously resolved to change the legal representative of Shenzhen Aidigong from Ms. Zhu Yufei to Ms. Wang Aier. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcements.

On 29 April 2025, the Company was notified that Guangdong Wanjia has received a notice regarding an arbitration (the “**SZA Arbitration**”) initiated in the name of Shenzhen Aidigong against Guangdong Wanjia and Shenzhen Common Splendor Investment Funds Management Company Limited\* (深圳同佳投資基金管理有限公司), an indirect wholly owned subsidiary of the Company (“**Shenzhen Common Splendor**”).

Based on the application for the SZA Arbitration, Shenzhen Aidigong sought for decisions that Guangdong Wanjia and Shenzhen Common Splendor jointly pay to Shenzhen Aidigong (i) the principal amount of approximately RMB95.3 million, (ii) the related accrued interest and damages of approximately RMB63.9 million, (iii) the legal fees of RMB1.8 million, and (iv) other costs and expenses in relation to the SZA Arbitration. It was alleged that (i) Shenzhen Aidigong has advanced loans to Shenzhen Common Splendor from September 2019 to July 2022, and (ii) Shenzhen Aidigong, Guangdong Wanjia and Shenzhen Common Splendor entered into an agreement in December 2022 to transfer the debt owed by Shenzhen Common Splendor to Shenzhen Aidigong (the “**Debt**”) to Guangdong Wanjia, while Shenzhen Common Splendor shall bear joint guarantee liabilities in relation to the Debt.

The Company noted that the application of the SZA Arbitration dated 14 February 2025 appeared to be stamped with the company chop of Shenzhen Aidigong. However, the current board of directors and legal representative of Shenzhen Aidigong have not authorized the initiation of the SZA Arbitration or the use of the company chop of Shenzhen Aidigong for such purpose.

The Company is of the view that that Ms. Zhu Yufei might have initiated the SZA Arbitration in the name of Shenzhen Aidigong without due authorisation from Shenzhen Aidigong or the Group, as she refused to return the registered company chop and other relevant company assets of Shenzhen Aidigong to the Group despite the Change of Legal Representative, so that the registered company chop of Shenzhen Aidigong remains in her possession, which appeared to have been used for the application for the SZA Arbitration.

The Group is consulting its PRC legal adviser regarding the SZA Arbitration and any unauthorized conduct of Ms. Zhu Yufei. The Group expects that it will defend the SZA Arbitration to protect its interests and reserves the right to take all necessary legal actions regarding any unauthorized conduct of Ms. Zhu Yufei. The Company will make further announcement(s) to update the shareholders and potential investors of the Company when appropriate.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Wong Wing Cheung**  
*Company Secretary*

Hong Kong, 30 April 2025

*As at the date of this announcement, the Board comprises Mr. Huang Wenhua, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Lee Kar Lung as a non-executive Director; and Mr. Shan Guoxin, Mr. Chu Pui Ki Dickson and Mr. Wang Bin as independent non-executive Directors.*

*\* For identification purposes only*